See more : Ningbo Donly Co.,Ltd (002164.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Ocumension Therapeutics (1477.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ocumension Therapeutics, a leading company in the Biotechnology industry within the Healthcare sector.
- Ahjikan Co., Ltd. (2907.T) Income Statement Analysis – Financial Results
- AB Electrolux (publ) (ELUX-A.ST) Income Statement Analysis – Financial Results
- Doric Nimrod Air One Limited (DNA.L) Income Statement Analysis – Financial Results
- Nanoforce, Inc. (NNFC) Income Statement Analysis – Financial Results
- United Internet AG (UTDI.DE) Income Statement Analysis – Financial Results
Ocumension Therapeutics (1477.HK)
About Ocumension Therapeutics
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 246.37M | 158.96M | 56.15M | 13.10M | 190.00K | 0.00 |
| Cost of Revenue | 102.00M | 56.04M | 19.21M | 1.72M | 10.00K | 0.00 |
| Gross Profit | 144.37M | 102.92M | 36.94M | 11.37M | 180.00K | 0.00 |
| Gross Profit Ratio | 58.60% | 64.74% | 65.78% | 86.84% | 94.74% | 0.00% |
| Research & Development | 123.77M | 184.31M | 169.06M | 179.55M | 99.46M | 40.68M |
| General & Administrative | 196.14M | 190.75M | 126.16M | 273.94M | 7.24M | 3.57M |
| Selling & Marketing | 82.86M | 183.04M | 127.65M | 50.73M | 2.48M | 0.00 |
| SG&A | 279.01M | 373.79M | 253.81M | 324.67M | 9.72M | 3.57M |
| Other Expenses | -258.41M | -6.96M | -382.00K | -5.02M | 49.95M | -158.74M |
| Operating Expenses | 144.37M | 551.14M | 422.48M | 499.20M | 159.13M | 49.45M |
| Cost & Expenses | 646.44M | 607.18M | 441.69M | 500.92M | 159.14M | 49.45M |
| Interest Income | 21.92M | 28.22M | 26.89M | 14.25M | 3.88M | 25.00K |
| Interest Expense | 1.33M | 1.79M | 567.00K | 59.00K | 63.00K | 5.00K |
| Depreciation & Amortization | 57.54M | 40.46M | 13.90M | 4.65M | 1.21M | 18.00K |
| EBITDA | -320.62M | -359.98M | -371.30M | -2.26B | -1.32B | -59.32M |
| EBITDA Ratio | -130.14% | -224.45% | -661.32% | -17,316.62% | -702,625.79% | 0.00% |
| Operating Income | -402.15M | -397.23M | -385.20M | -2.27B | -1.34B | -49.45M |
| Operating Income Ratio | -163.23% | -249.90% | -686.07% | -17,352.15% | -703,261.58% | 0.00% |
| Total Other Income/Expenses | 22.67M | -5.00M | 125.55M | -1.78B | -1.17B | -159.96M |
| Income Before Tax | -379.48M | -402.23M | -259.99M | -2.26B | -1.33B | -209.41M |
| Income Before Tax Ratio | -154.03% | -253.04% | -463.06% | -17,294.33% | -697,621.58% | 0.00% |
| Income Tax Expense | 307.00K | 414.00K | -125.21M | -7.57M | -23.89M | -159.95M |
| Net Income | -379.79M | -402.64M | -134.78M | -2.26B | -1.30B | -207.61M |
| Net Income Ratio | -154.15% | -253.30% | -240.06% | -17,236.52% | -685,050.00% | 0.00% |
| EPS | -0.59 | -0.64 | -0.22 | -7.47 | -2.26 | -0.36 |
| EPS Diluted | -0.59 | -0.64 | -0.22 | -7.47 | -2.26 | -0.36 |
| Weighted Avg Shares Out | 649.19M | 632.53M | 607.14M | 302.35M | 575.25M | 575.25M |
| Weighted Avg Shares Out (Dil) | 649.19M | 632.53M | 607.14M | 302.35M | 575.25M | 575.25M |
Source: https://incomestatements.info
Category: Stock Reports